유럽의 정밀의료 소프트웨어 시장 : 제품 유형별, 용도별, 최종사용자별, 국가별 - 분석과 예측(2024-2033년)

Introduction to Europe Precision Medicine Software Market

The Europe precision medicine software market was valued at $460.9 million in 2024 and is expected to reach $1,224.7 million by 2033, growing at a CAGR of 11.47% between 2024 and 2033. In the Europe market, precision medicine software refers to advanced digital tools and applications designed to support the implementation of precision medicine in healthcare. This personalized approach focuses on tailoring medical treatments and decisions to individual patient characteristics, including genetics, lifestyle, environment, and molecular or cellular profiles.

Market Introduction

The market for precision medicine software in Europe is expanding significantly due to developments in data analytics, genomics, and tailored healthcare strategies. In order to customize medical choices and treatments to each patient's unique genetic profile, lifestyle, and environmental circumstances, precision medicine software is essential. By enabling data-driven decision-making, this technology enhances patient outcomes, treatment effectiveness, and diagnostic precision.

Precision medicine software adoption is being accelerated by Europe's strong healthcare system and rising investments in digital health initiatives. Through programs like Horizon Europe, governments and organizations throughout the continent are giving genetic research and precision healthcare top priority, which is encouraging innovation in the field. The software's capabilities are further improved by the integration of artificial intelligence (AI) and machine learning (ML), which permits real-time data analysis and customized treatment planning.

In Europe, pharmacogenomics, chronic disease management, uncommon disease detection, and oncology are among the main uses of precision medicine software. The increased emphasis on precision healthcare, along with developments in bioinformatics and big data, is propelling market expansion despite obstacles such data privacy issues and high implementation costs.

The market for precision medicine software is expected to be crucial in improving patient care and advancing personalized medicine, as Europe continues to lead the world in the adoption of cutting-edge healthcare technologies.

Market Segmentation

Segmentation 1: by Delivery Mode

• On-Premises Delivery Mode
• Cloud-Based Delivery Mode

Segmentation 2: by Application

• Oncology
• Cardiovascular
• Rare Diseases
• Others

Segmentation 3: by End User

• Healthcare Providers
• Research Centers and Government Institutes
• Pharmaceutical and Biotechnology Companies
• Other End Users

Segmentation 4: by Country

• Germany
• U.K.
• France
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Product/Innovation Strategy: The Europe precision medicine software market has been segmented based on various categories, such as product type, application, and end user.

Competitive Strategy: The Europe precision medicine software market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the precision medicine software market analyzed and profiled in the study involve established players that offer various kinds of products.

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• F. Hoffmann-La Roche Ltd
• Genedata AG
• Koninklijke Philips N.V.
• QIAGEN N.V.
• SOPHiA GENETICS SA

Table of Contents

Executive Summary

Scope and Definition

1 Markets

• 1.1 Trends: Current and Future Impact Assessment
  • 1.1.1 Rise in Personalized Healthcare
  • 1.1.2 Cloud-Based Delivery Mode-Based Platforms Elevating Data Accessibility
• 1.2 Supply Chain Overview
  • 1.2.1 Value Chain Analysis
• 1.3 Regulatory Landscape
• 1.4 Market Dynamics Overview
  • 1.4.1 Market Drivers
    • 1.4.1.1 Utilizing Artificial Intelligence and Precision Medicine Together
    • 1.4.1.2 Enhancement in the Precision Medicine Field Using Integrated and Automated Solutions
  • 1.4.2 Market Restraints
    • 1.4.2.1 Data Safety and Privacy Concerns
  • 1.4.3 Market Opportunities
    • 1.4.3.1 Leveraging Electronic Health Records in the Market

2 Regions

• 2.1 Regional Summary
• 2.2 Drivers and Restraints
• 2.3 Europe
  • 2.3.1 Regional Overview
  • 2.3.2 Driving Factors for Market Growth
  • 2.3.3 Factors Challenging the Market
  • 2.3.4 Application
  • 2.3.5 Product
  • 2.3.6 France
  • 2.3.7 Germany
  • 2.3.8 U.K.
  • 2.3.9 Spain
  • 2.3.10 Italy
  • 2.3.11 Rest-of-Europe

3 Markets Competitive Benchmarking & Company Profiles

• 3.1 Next Frontiers
• 3.2 Geographic Assessment
  • 3.2.1 F. Hoffmann-La Roche Ltd
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products/Product Portfolio
    • 3.2.1.3 Target Customers
    • 3.2.1.4 Key Personnel
    • 3.2.1.5 Analyst View
  • 3.2.2 Genedata AG
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products/Product Portfolio
    • 3.2.2.3 Target Customers
    • 3.2.2.4 Key Personnel
    • 3.2.2.5 Analyst View
  • 3.2.3 Koninklijke Philips N.V.
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products/Product Portfolio
    • 3.2.3.3 Target Customers
    • 3.2.3.4 Key Personnel
    • 3.2.3.5 Analyst View
  • 3.2.4 QIAGEN N.V.
    • 3.2.4.1 Overview
    • 3.2.4.2 Top Products/Product Portfolio
    • 3.2.4.3 Target Customers
    • 3.2.4.4 Key Personnel
    • 3.2.4.5 Analyst View
  • 3.2.5 SOPHiA GENETICS SA
    • 3.2.5.1 Overview
    • 3.2.5.2 Top Products/Product Portfolio
    • 3.2.5.3 Target Customers
    • 3.2.5.4 Key Personnel
    • 3.2.5.5 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast